Medical Innovations

Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe

Annonce événementielle au sens de l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer

Basel, June 22, 2022 — Novartis announced today that the European Commission (EC) approved Tabrecta® (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy…

Reimagine MedicineOncologyMedical InnovationsCancer
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

Basel, June 6, 2022 — Novartis today announced Tafinlar® (dabrafenib) + Mekinist® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade glioma (pLGG) requiring first systemic treatment compared to chemotherapy, the current standard-of-care for these patients1. In this study, patients…

Reimagine MedicineOncologyMedical InnovationsCancer
New Novartis data show Piqray® effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancer

Basel, June 3, 2022 — Novartis today announced results of an exploratory retrospective biomarker analysis finding that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect treatment benefit with Piqray® (alpelisib) plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor-…

Reimagine MedicineOncologyMedical InnovationsCancer
New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer

Basel, June 3, 2022 — Novartis today announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer. These data will be presented at the…

Reimagine MedicineOncologyMedical InnovationsCancer
New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients

Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. The analysis of…

Reimagine MedicineOncologyMedical InnovationsCancer
Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme

Annonce événementielle selon l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meeting

Basel, April 11, 2022 — Novartis today announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR). Comprehensive information on the discovery of JDQ443 is also included in a poster being presented on…

Reimagine MedicineOncologyMedical InnovationsCancer